fluorouracil + epirubicin + cyclophosphamide + docetaxel + trastuzumab

This is a combination chemotherapy and targeted therapy regimen used for the treatment of HER2-positive breast cancer. The regimen combines: 1. Fluorouracil - an antimetabolite chemotherapy drug that interferes with DNA synthesis 2. Epirubicin - an anthracycline chemotherapy drug that inhibits DNA and RNA synthesis 3. Cyclophosphamide - an alkylating agent that damages DNA 4. Docetaxel - a taxane chemotherapy drug that disrupts microtubule function 5. Trastuzumab (Herceptin) - a monoclonal antibody that targets HER2 receptors This combination is typically used in the treatment of HER2-positive breast cancer, particularly in the adjuvant or neoadjuvant setting. Trastuzumab specifically targets the HER2 protein on cancer cells, while the chemotherapy agents work through various mechanisms to kill rapidly dividing cells.